The success rate of Axitinib is around 90.7 percent.
However the success rate of Axitinib will depend on the type of cancer that is being treated with Axitinib and the stage of cancer.
The drug Axitinib is a selective inhibitor of VEGF receptors 1, 2 and 3 and is used to treat metastatic renal cell carcinoma and metastatic head cancer and neck cancer.
For treating Metastatic renal cell carcinoma the success rate of Axitinib is 90.75 percent.
And for Metastatic head cancer and neck cancer the success rate is 71%.
The cancer treatment drug Axitinib is often used as a second line cancer treatment for mRCC, after sunitinib or cytokines.
Radical nephrectomy is historically accepted as the standard treatment for localized renal cell carcinoma (RCC).
Axitinib is not a traditional chemotherapy drug and instead Axitinib has a different way of working than chemotherapy drugs.
The drug Axitinib works by targeting the cancer cells to stop them growing and spreading.
The treatment with the drug Axitinib is continuous.
The drug Axitinib has been approved for the treatment of advanced kidney cancer as either a first treatment option or second treatment option.
Axitinib is used as a first treatment option when combined with a medication that stimulates the immune system (immunotherapy), either avelumab or pembrolizumab.